Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation. Frontiers in human neuroscience Wong, J. K., Mayberg, H. S., Wang, D. D., Richardson, R. M., Halpern, C. H., Krinke, L., Arlotti, M., Rossi, L., Priori, A., Marceglia, S., Gilron, R., Cavanagh, J. F., Judy, J. W., Miocinovic, S., Devergnas, A. D., Sillitoe, R. V., Cernera, S., Oehrn, C. R., Gunduz, A., Goodman, W. K., Petersen, E. A., Bronte-Stewart, H., Raike, R. S., Malekmohammadi, M., Greene, D., Heiden, P., Tan, H., Volkmann, J., Voon, V., Li, L., Sah, P., Coyne, T., Silburn, P. A., Kubu, C. S., Wexler, A., Chandler, J., Provenza, N. R., Heilbronner, S. R., Luciano, M. S., Rozell, C. J., Fox, M. D., de Hemptinne, C., Henderson, J. M., Sheth, S. A., Okun, M. S. 2022; 16: 1084782

Abstract

The deep brain stimulation (DBS) Think Tank X was held on August 17-19, 2022 in Orlando FL. The session organizers and moderators were all women with the theme women in neuromodulation. Dr. Helen Mayberg from Mt. Sinai, NY was the keynote speaker. She discussed milestones and her experiences in developing depression DBS. The DBS Think Tank was founded in 2012 and provides an open platform where clinicians, engineers and researchers (from industry and academia) can freely discuss current and emerging DBS technologies as well as the logistical and ethical issues facing the field. The consensus among the DBS Think Tank X speakers was that DBS has continued to expand in scope however several indications have reached the "trough of disillusionment." DBS for depression was considered as "re-emerging" and approaching a slope of enlightenment. DBS for depression will soon re-enter clinical trials. The group estimated that globally more than 244,000 DBS devices have been implanted for neurological and neuropsychiatric disorders. This year's meeting was focused on advances in the following areas: neuromodulation in Europe, Asia, and Australia; cutting-edge technologies, closed loop DBS, DBS tele-health, neuroethics, lesion therapy, interventional psychiatry, and adaptive DBS.

View details for DOI 10.3389/fnhum.2022.1084782

View details for PubMedID 36819295